The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Open accessAbstract
BACKGROUND: alteration. Data are needed to confirm and expand on the findings of the phase 2 study. METHODS: alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). We randomly assigned the patients in a 2:1 ratio to receive oral rucaparib (600 mg twice daily) or a physician's choice control (docetaxel or a second-generation ARPI [abiraterone acetate or enzalutamide]). The primary outcome was the median duration of imaging-based progression-free survival according to independent review. RESULTS: alteration. At 62 months, the duration of imaging-based progression-free survival was significantly longer in the rucaparib group than in the control group, both in the BRCA subgroup (median, 11.2 months and 6.4 months, respectively; hazard ratio, 0.50; 95% confidence interval [CI], 0.36 to 0.69) and in the intention-to-treat group (median, 10.2 months and 6.4 months, respectively; hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001 for both comparisons). In an exploratory analysis in the ATM subgroup, the median duration of imaging-based progression-free survival was 8.1 months in the rucaparib group and 6.8 months in the control group (hazard ratio, 0.95; 95% CI, 0.59 to 1.52). The most frequent adverse events with rucaparib were fatigue and nausea. CONCLUSIONS: alteration. (Funded by Clovis Oncology; TRITON3 ClinicalTrials.gov number, NCT02975934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 3 randomized trials PROfound (NCT02987543), and TRITON-3 (NCT02975934), treatment with PARP inhibitors was favored in both chemotherapy-naïve patients and those who had received prior taxane-based chemotherapy [57, 58].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an exploratory analysis of a subgroup of TRITON-3 evaluating patients with BRCA alterations, the median PFS with rucaparib (11.2 months) was longer than with docetaxel (6.4 months; p < 0.001) [57].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Self-citationAshworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Flagged first, then by citations
Research works printed but not linked: 2
- Rubraca (rucaparib) tablets. Boulder, CO: Clovis Oncology, 2022 (package insert).
- Lynparza (olaparib) tablets. Wilmington, DE: AstraZeneca Pharmaceuticals, 2022 (package insert).
Cited by
Sorted by citations
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D. A., Bitting, R. L., Bryce, A. H., Chapin, B. F., Cheng, H. H., D'Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 623
Self-citationAgarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01055-3 · Cited by 538
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 468
Raychaudhuri, R., Lin, D. W., & Montgomery, B. (2025) · JAMA · doi:10.1001/jama.2025.0228 · Cited by 429
Tilki, D., van den Bergh, R. C. N., Briers, E., den Broeck, T. V., Brunckhorst, O., Darraugh, J., Eberli, D., Meerleer, G. D., Santis, M. D., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 407
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01653-2 · Cited by 362
Self-citationSPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
Hróbjartsson, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081660 · Cited by 171
Fizazi, K. S., Azad, A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., Jones, R. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02704-x · Cited by 154
Self-citationGillessen, S., Turco, F., Davis, I. D., Efstathiou, J. A., Fizazi, K. S., James, N. D., Shore, N. D., Small, E. J., Smith, M. R., Sweeney, C. J., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.09.017 · Cited by 150
Self-citationCastration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
Le, T. K., Duong, Q. H., Baylot, V., Fargette, C., Baboudjian, M., Colleaux, L., Taïeb, D., & Rocchi, P. (2023) · Cancers · doi:10.3390/cancers15205047 · Cited by 125
Abida, W. M., Campbell, D. C., Patnaik, A., Bryce, A. H., Shapiro, J. D., Bambury, R. M., Zhang, J., Burke, J. M., Castellano, D., Pous, A. F., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.05.021 · Cited by 119
Self-citationClinical approaches to overcome PARP inhibitor resistance
Zou, Y., Zhang, H., Chen, P., Tang, J., Yang, S., Nicot, C., Guan, Z., Li, X., & Tang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02355-1 · Cited by 118
Mateo, J., Bono, J. S. D., Fizazi, K. S., Fred Saad, C., Shore, N. D., Sandhu, S. K., Chi, K. N., Agarwal, N., Olmos, D., Thiery-Vuillemin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00339 · Cited by 108
Self-citationPARP inhibitors in metastatic prostate cancer
Taylor, A. K., Kosoff, D., Emamekhoo, H., Lang, J. M., & Kyriakopoulos, C. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1159557 · Cited by 99
Olmos, D., Lorente, D., Alameda, D., Cattrini, C., Romero-Laorden, N., Lozano, R., Lopez-Casas, P. P., Jambrina, A., Capone, C., Broecke, A. M. V., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.01.011 · Cited by 94
Fallah, J., Xu, J., Weinstock, C., Gao, X., Heiss, B. L., Maguire, W. F., Chang, E., Agrawal, S., Tang, S., Amiri-Kordestani, L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02105 · Cited by 86
Attard, G., Agarwal, N., Graff, J. N., Sandhu, S. K., Efstathiou, E., Özgüroğlu, M., Gomes, A. J., Vianna, K., Luo, H., Gotto, G. T., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03961-8 · Cited by 80
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Khamidullina, A. I., Abramenko, Y. E., Bruter, A. V., & Tatarskiy, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021263 · Cited by 73
Garje, R., Riaz, I. B., Naqvi, S. A. A., Rumble, R. B., Taplin, M., Kungel, T. M., Herchenhorn, D., Zhang, T., Beckermann, K. E., Vapiwala, N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00007 · Cited by 73
Self-citationBRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Cheng, H. H., Shevach, J. W., Castro, E., Couch, F. J., Domchek, S. M., Eeles, R. A., Giri, V. N., Hall, M. J., King, M., Lin, D. W., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2185 · Cited by 63
Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline
Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02608 · Cited by 64
Fizazi, K. S., Chi, K. N., Shore, N. D., Herrmann, K., Bono, J. S. D., Castellano, D., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.07.003 · Cited by 59
Self-citationAgarwal, N., Azad, A., Carles, J., Fay, A. P., Matsubara, N., Szczylik, C. A., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00684-1 · Cited by 61
Self-citationChen, G., Zheng, D.-X., Zhou, Y., Du, S., & Zeng, Z. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216507 · Cited by 57
Advances in the treatment of metastatic prostate cancer
Gebrael, G., Fortuna, G. G., Sayegh, N., Swami, U., & Agarwal, N. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.06.009 · Cited by 56
Fallah, J., Xu, J., Weinstock, C., Brave, M. H., Bloomquist, E. W., Fiero, M. H., Schaefer, T., Pathak, A. B., Abukhdeir, A. M., Bhatnagar, V., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01868 · Cited by 56
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
Seed, G., Beije, N., Yuan, W., Bertan, C. M., Goodall, J. R., Lundberg, A., Tyler, M., Figueiredo, I., Pereira, R., Baker, C., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.015 · Cited by 57
Development of PARP inhibitors in advanced prostate cancer
Bourlon, M. T., Valdez-Sandoval, P. I., & Castro, E. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231221337 · Cited by 53
The contemporary management of prostate cancer
Chakrabarti, D., Albertsen, P. C., Adkins, A., Kishan, A. U., Murthy, V., Parker, C. C., Pathmanathan, A. U., Reid, A. H. M., Sartor, O., van As, N. J., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70020 · Cited by 50
Maekawa, S., Takata, R., & Obara, W. (2024) · Cancers · doi:10.3390/cancers16030523 · Cited by 49
Fizazi, K. S., Azad, A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., Jones, R. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00683-x · Cited by 46
Self-citationImpact of DNA damage repair alterations on prostate cancer progression and metastasis
Lukashchuk, N., Barnicle, A., Adelman, C. A., Armenia, J., Kang, J., Barrett, J. C., & Harrington, E. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1162644 · Cited by 43
Naqvi, S. A. A., Riaz, I. B., Bibi, A., Khan, M. A., Imran, M., Khakwani, K. Z. R., Raina, A., Anjum, M. U., Cobran, E. K., Warner, J. L., et al. (2025) · European Urology · doi:10.1016/j.eururo.2024.12.007 · Cited by 41
Self-citationAgarwal, N., Zhang, T., Efstathiou, E., Sayegh, N., Engelsberg, A., Fred Saad, C., & Fizazi, K. S. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113249 · Cited by 38
Self-citationFrancini, E., Agarwal, N., Castro, E., Cheng, H. H., Chi, K. N., Clarke, N. W., Mateo, J., Rathkopf, D. E., Fred Saad, C., & TOMBAL, B. F. (2024) · European Urology · doi:10.1016/j.eururo.2024.09.008 · Cited by 37
Fizazi, K. S., Attard, G., Azad, A. A., Baciarello, G., Beltran, H., Bjartell, A., Blanchard, P., Bossaert, F., Castro, E., Comperat, E., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.015 · Cited by 35
Self-citationGenetic and biological drivers of prostate cancer disparities in Black men
Gong, J., Kim, D. M., Freeman, M. R., Kim, H. L., Ellis, L., Smith, B., Theodorescu, D., Posadas, E. M., Figlin, R. A., Bhowmick, N. A., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00828-w · Cited by 38
PARP inhibitors for prostate cancer
Longoria, O., Beije, N., & de Bono, J. S. (2024) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.09.003 · Cited by 34
Iannantuono, G. M., Chandran, E. B. A., Floudas, C. S., Choo‐Wosoba, H., Butera, G., Roselli, M., Gulley, J. L., & Karzai, F. H. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102623 · Cited by 35
Παναγοπούλου, Μ., Panou, T., Γκουντάκος, Α., Tarapatzi, G., Karaglani, M., Tsamardinos, I., & Chatzaki, Ε. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01787-8 · Cited by 34
McManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00906-z · Cited by 32
“Several multivariable models are available that incorporate these factors to help inform prognoses for patients with mCRPC [48 – 50], and prognostic knowledge from these models may inform treatment decision-making.”
Knutson, T. P., Luo, B., Kobilka, A., Lyman, J., Guo, S., Munro, S. A., Li, Y., Heer, R., Gaughan, L., Morris, M. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54847-1 · Cited by 33
Self-citationChen, X., Wang, M., Wang, H., Yang, J., Li, X., Zhang, R., Ding, X., Hou, H., Zhou, J., & Wu, M. Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117366 · Cited by 31
Olmos, D., Lorente, D., Jambrina, A., Velasco, D., Ovejero-Sánchez, M., Ginel, I. G., Romero-Laorden, N., Nunes‐Carneiro, D., Balongo, M., Gutiérrez-Pecharromán, A., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.534 · Cited by 31
Bauckneht, M., Ciccarese, C., Laudicella, R., Mosillo, C., D’Amico, F., Anghelone, A., Strusi, A., Beccia, V., Sergio Bracarda, A., Fornarini, G., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102698 · Cited by 32
Heiss, B. L., Chang, E., Gao, X., Truong, T. M., Brave, M. H., Bloomquist, E. W., Shah, A. B., Hamed, S. S., Kraft, J. B., Chiu, H.-J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02182 · Cited by 28
Side effects of prostate cancer therapies and potential management
Xiao, J., Zhang, M., & Wu, D. (2024) · Journal of Biological Methods · doi:10.14440/jbm.2024.0019 · Cited by 28
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Chehade, C. H., Gebrael, G., Sayegh, N., Özay, Z. İ., Narang, A., Crispino, T., Golan, T., Litton, J. K., Swami, U., Moore, K. N., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21870 · Cited by 28
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Beije, N., Abida, W. M., Antonarakis, E. S., Castro, E., de Wit, R., Fizazi, K. S., Gillessen, S., Hussain, M., Mateo, J., Morris, M. J., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.03.038 · Cited by 27
Self-citationEmerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond
Kim, I.-H. (2023) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2024.24.e6 · Cited by 27
Grypari, I. M., Tzelepi, V., & Gyftopoulos, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411418 · Cited by 26
Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Yu, F., Liu, Z., Chen, Y., & He, Z. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02844-7 · Cited by 26
Genetics of prostate cancer: a review of latest evidence
Hall, R. R., Bancroft, E. K., Pashayan, N., Kote‐Jarai, Z., & Eeles, R. A. (2024) · Journal of Medical Genetics · doi:10.1136/jmg-2024-109845 · Cited by 26
CACA guidelines for holistic integrative management of prostate cancer
Dai, B., Wang, H., Shi, B., Xing, J., Zhu, S., He, Z., Zou, Q., Wei, Q., Bi, J., Bian, J., et al. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00118-4 · Cited by 24
Shui, I. M., Burcu, M., Shao, C., Chen, C., Liao, C.-Y., Jiang, S., Cristescu, R., & Parikh, R. B. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00764-1 · Cited by 24
The past and present of prostate cancer and its treatment and diagnostics: A historical review
Lehtonen, M., & Kellokumpu‐Lehtinen, P. (2023) · SAGE Open Medicine · doi:10.1177/20503121231216837 · Cited by 25
Orme, J. J., Taza, F., Sarkar, N. D., Tewari, A. K., Naqvi, S. A. A., Riaz, I. B., Childs, D. S., Omar, N. S., Adra, N., Ashkar, R., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.11.014 · Cited by 23
Self-citationPark, J. J., Chu, A., Li, J., Ali, A., McKay, R. R., Hwang, C., Labriola, M., Jang, A., Kilari, D., Mo, G., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00567 · Cited by 24
Lampe, H., Tam, L., & Hansen, A. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399802 · Cited by 21
Kostos, L. K., Tran, B., & Azad, A. (2024) · Drugs · doi:10.1007/s40265-024-02071-y · Cited by 22
Pal, T., Schon, K. R., Astiazarán-Symonds, E., Balmañà, J., Foulkes, W. D., James, P. A., Klugman, S. D., Livinski, A. A., Mak, J. S., Ngeow, J. Y. Y., et al. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2024.101243 · Cited by 22
TP53 Deficiency in the Natural History of Prostate Cancer
Ofner, H., Kramer, G., Shariat, S. F., & Hassler, M. R. (2025) · Cancers · doi:10.3390/cancers17040645 · Cited by 23
Synergistic targeting strategies for prostate cancer
Li, X., Han, Z., & Ai, J. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01042-6 · Cited by 22
Management of Advanced Prostate Cancer in the Precision Oncology Era
Gillette, C. M., Yette, G. A., Cramer, S. D., & Graham, L. S. (2023) · Cancers · doi:10.3390/cancers15092552 · Cited by 21
Marshall, C. H., Teply, B. A., Lu, J., Oliveira, L., Wang, H., Mao, S. S., Kelly, W. K., Paller, C. J., Markowski, M. C., Denmeade, S. R., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3074 · Cited by 21
Gazola, A. A., Lautert-Dutra, W., Archangelo, L. F., dos Reis, R. B., & Squire, J. A. (2024) · Molecular Cytogenetics · doi:10.1186/s13039-024-00698-w · Cited by 21
Gui, F., Jiang, B., Jiang, J., He, Z., Tsujino, T., Takai, T., Arai, S., Pana, C., Köllermann, J. W., Bradshaw, G. A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu0847 · Cited by 21
Al-Akhras, A., Chehade, C. H., Narang, A., & Swami, U. (2024) · Life · doi:10.3390/life14020198 · Cited by 20
The Landscape of PARP Inhibitors in Solid Cancers
Muzzana, M., Broggini, M., & Damia, G. L. M. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s499226 · Cited by 19
Wang, Y.-W., Allen, I., Funingana, I.-G., Tischkowitz, M. D., & Joko-Fru, W. Y. (2025) · BJC Reports · doi:10.1038/s44276-025-00122-9 · Cited by 20
Aggarwal, R. R., Vuky, J., VanderWeele, D. J., Rettig, M. B., Heath, E. I., Quigley, D. A., Huang, J., Chumber, A. K., Cheung, A., Foye, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01989 · Cited by 19
Advances in Targeted Therapy for Metastatic Prostate Cancer
Grewal, K., Dorff, T. B., Mukhida, S. S., Agarwal, N., & Hahn, A. W. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01323-7 · Cited by 20
Sayyid, R. K., Klaassen, Z. W. A., Berlín, A., Roy, S., Brandão, L. R., Bernardino, R. M. M., Chavarriaga, J., Jiang, D., Spratt, D. E., Fleshner, N. E., et al. (2023) · British Journal of Urology · doi:10.1111/bju.16130 · Cited by 18
Maiorano, B. A., Giorgi, U. D., Verzoni, E., Maiello, E., Procopio, G., Conteduca, V., Maïo, M. D., & the MeetURO group (2023) · Targeted Oncology · doi:10.1007/s11523-023-01016-x · Cited by 19
McKay, R. R., Morgans, A. K., Shore, N. D., Dunshee, C. J., Devgan, G., & Agarwal, N. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102726 · Cited by 18
Markowski, M. C., Sternberg, C. N., Wang, H., Wang, T., Linville, L. M., Marshall, C. H., Sullivan, R., King, S., Lotan, T. L., & Antonarakis, E. S. (2024) · The Oncologist · doi:10.1093/oncolo/oyae120 · Cited by 18
Chen, Y., & Lan, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1451957 · Cited by 18
New Therapeutic Options for BRCA Mutant Patients
Ghanem, A., & Domchek, S. M. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-082523-083843 · Cited by 17
Targeting AURKA with multifunctional nanoparticles in CRPC therapy
Deng, B., Ke, B., Tian, Q., Gao, Y., Zhai, Q., & Zhang, W. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03070-7 · Cited by 16
Yang, W., Chen, H., Ma, L., Dong, J., Wei, M., Xue, X., Li, Y., Jin, Z., Xu, W., & Ji, Z. (2023) · iScience · doi:10.1016/j.isci.2023.107617 · Cited by 17
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
Catalano, M., Lapucci, A., Nobili, S., Aquino, I. D. G., Vascotto, I. A., Antonuzzo, L., Villari, D., Nesi, G., Mini, E., & Roviello, G. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04604-w · Cited by 17
Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer
LaRose, M., Manji, G. A., & Bates, S. E. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.11.001 · Cited by 16
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients
Vasseur, D., Arbab, A., Giudici, F., Marzac, C., Michiels, S., Tagliamento, M., Bayle, A., Smolenschi, C., Sakkal, M., Aldea, M. D., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00544-7 · Cited by 18
Telomere-related DNA damage response pathways in cancer therapy: prospective targets
Gu, L., Liu, M., Zhang, Y., Zhou, H., Wang, Y., & Xu, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1379166 · Cited by 17
Parps in immune response: Potential targets for cancer immunotherapy
Wang, S., Huang, J., Zeng, T., Chen, Y., Xu, Y., & Zhang, B. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116803 · Cited by 18
Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair
Herberts, C., Wyatt, A. W., Nguyen, P. L., & Cheng, H. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390384 · Cited by 15
Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors
Szentmártoni, G., Mühl, D., Csanda, R., Szász, A. M., Herold, Z., & Dank, M. (2024) · Biomedicines · doi:10.3390/biomedicines12030593 · Cited by 15
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
Miller, C. D., Likasitwatanakul, P., Toye, E., Hwang, J. H., & Antonarakis, E. S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2405103 · Cited by 15
Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D’Agostino, E., Pirola, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094624 · Cited by 15
Hsiao, S. J., Black, D. R., Devereaux, K. A., Hagemann, I. S., Jennings, L. J., Mandelker, D. L., Paulson, V., Shiller, M., Stockley, T. L., Vail, E., et al. (2025) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2025.05.003 · Cited by 14
Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications
Hernandez‐Martinez, J., Rosell, R., & Arrieta, O. G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104058 · Cited by 15
Shevach, J. W., Candelieri-Surette, D., Lynch, J. A., Hubbard, R. A., Alba, P. R., Glanz, K., Parikh, R. B., & Maxwell, K. N. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7105 · Cited by 14
Ciccarese, C., Bauckneht, M., Zagaria, L., Fornarini, G., Beccia, V., Lanfranchi, F., Perotti, G., Pinterpe, G., Migliaccio, F., Tortora, G., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01117-1 · Cited by 14
A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer
Sooi, K. W. X., Walsh, R., Kumarakulasinghe, N. B., Wong, A., & Ngoi, N. Y. L. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.48 · Cited by 14
Bowling, G. C., Swargaloganathan, P., Heintz, C., Madan, R. A., Eldhose, B., Dobi, A. L., & Chesnut, G. T. (2023) · Cancers · doi:10.3390/cancers15194904 · Cited by 13
DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer
Akhoundova, D., Francica, P., Rottenberg, S., & Rubin, M. A. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000422 · Cited by 13
Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair
Altwerger, G. H., Ghazarian, M., & Glazer, P. M. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.007 · Cited by 13
Ditonno, F., Bianchi, A., Malandra, S., Porcaro, A. B., Fantinel, E., Negrelli, R., Ferro, M., Milella, M., Brunelli, M., Riccardo Autorino, B., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.12.011 · Cited by 13
Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends
Thapa, B., Sarkar, N. D., Giri, S., Sharma, K., Kim, M., & Kilari, D. (2024) · Cancer Management and Research · doi:10.2147/cmar.s411023 · Cited by 13
Serritella, A. V., Taylor, A. K., Haffner, M. C., Abida, W. M., Bryce, A. H., Karsh, L. I., Tagawa, S. T., Twardowski, P. W., Armstrong, A. J., & Lang, J. M. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00887-z · Cited by 13
Self-citation
Metadata
- Authors
- Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., Lindberg, H., Morris, D., Nolè, F., Staffurth, J., Redfern, C., Sáez, M. I., Abida, W., Daugaard, G., Heidenreich, A., Krieger, L., Sautois, B., Loehr, A., Despain, D., Heyes, C. A., Watkins, S. P., Chowdhury, S., Ryan, C. J., & Bryce, A. H.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Guy's Hospital (GB)
- University of Minnesota (US)
- ORCID
- Fizazi, Karim
- Piulats, Josep M.
- Reaume, M. Neil
- Ostler, Peter
- McDermott, Ray
- Gingerich, Joel R.
- Pintus, Elias
- Sridhar, Srikala S.
- Bambury, Richard M.
- Emmenegger, Urban
- Lindberg, Henriette
- Morris, David
- Nolè, Franco
- Staffurth, John
- Abida, Wassim
- Daugaard, Gedske
- Heidenreich, Axel
- Krieger, Laurence
- Sautois, Brieuc
- Loehr, Andrea
- Despain, Darrin
- Watkins, Simon P.
- Ryan, Charles J.
- Bryce, Alan H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-02-23
- Volume
- 388
- Issue
- 8
- Pages
- 719-732
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10064172
- OpenAlex
- W4321079951
- Cited by
- 449
- References
- 27
- Citations by year
- 2026: 91 · 2025: 134 · 2024: 139 · 2023: 85
- FWCI
- 82.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- Funders
- Clovis Oncology
- National Cancer Institute (P30-CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- rucaparib, metastatic prostate cancer, PARP inhibitors, BRCA mutations, ATM mutations, progression-free survival, androgen receptor pathway inhibitors, docetaxel, abiraterone, enzalutamide, PARP inhibitor resistance
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Docetaxel, Progression-Free Survival, Androgen Antagonists, Androstenes, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Indoles, Male, Nitriles, Phenylthiohydantoin, Disease Progression, Genes, BRCA1, Genes, BRCA2, Ataxia Telangiectasia Mutated Proteins, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
